Data demonstrated beneficial bacterial taxa persist in fecal samples from patients with rCDI despite

Axos Financial subsidiary Axos Nevada Holding plans to acquire Arc Technologies to expand Axos' arti

STATEN ISLAND, N.Y., July 8, 2026 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx

Results are from Acurx's ongoing scientific collaboration with Leiden University Medical Center (LUM

Acurx Pharmaceuticals (ACXP) might move higher on growing optimism about its earnings prospects, whi

Acurx Pharmaceuticals, Inc. (ACXP) Q1 2026 Earnings Call Transcript

STATEN ISLAND, N.Y., May 12, 2026 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx

DNA pol IIIC inhibitors demonstrate the unexpected benefit of gut microbiome preservation while demo

STATEN ISLAND, N.Y., April 29, 2026 /PRNewswire/ -- Acurx Pharmaceuticals (Nasdaq: ACXP) (Acurx or t

Staten Island, New York--(Newsfile Corp. - April 27, 2026) - Acurx Pharmaceuticals, Inc. (NASDAQ: AC

STATEN ISLAND, N.Y., April 20, 2026 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acu

$2.5 million upfront with up to an additional $4.6 million of potential aggregate gross proceeds upo

U.S. stocks higher, Dow up 100 points. NASDAQ and S&P 500 also see gains. Energy shares up, cons

$2.5 million upfront with up to an additional $4.6 million of potential aggregate gross proceeds upo

Here is how Acurx Pharmaceuticals, Inc. (ACXP) and Apyx Medical (APYX) have performed compared to th

Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) ("Acurx" or the "Company"), a late-stage b

STATEN ISLAND, N.Y., March 30, 2026 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acu

The mean of analysts' price targets for Acurx Pharmaceuticals (ACXP) points to a 226.3% upside in th

Here is how Acurx Pharmaceuticals, Inc. (ACXP) and Apyx Medical (APYX) have performed compared to th

Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP - Get Free Report) saw a significant decline in short inte

Acurx Pharmaceuticals, Inc. (ACXP) Q4 2025 Earnings Call Transcript

Acurx Pharmaceuticals (NASDAQ:ACXP) shares down on Friday after reporting net loss for Q4 2025, but

Acurx Pharmaceuticals (NASDAQ:ACXP) reported quarterly losses of $(0.73) per share which beat the an

STATEN ISLAND, N.Y., March 13, 2026 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acu

ACXP shares are falling Thursday as overbought signals trigger a pullback after Wednesday's 108%

Petco Health and Wellness (WOOF) reported strong Q4 sales, but missed earnings estimates. Other gain

Acurx Pharmaceuticals Inc shares are trading sharply higher Wednesday afternoon despite a lack of co

Acurx's Program in the Broader CDI Patient Population is Ready to Advance toPhase 3 Internationa

Acurx Pharmaceuticals (NASDAQ:ACXP) reported quarterly losses of $(1.23) per share which beat the an